Trial
NCT01585688
Phase I/II Study of hLL1-DOX in Relapsed NHL and CLL
Phase ITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Gilead Sciences
Collaborators
—
Condition
Non-Hodgkin's Lymphoma
Intervention
hLL1-DOX (IMMU-115)
Why stopped
Study was terminated due to lack of efficacy, as a result, the stability program for the drug product was discontinued
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-10-08